Will Image-guided Metastasis-directed Therapy Change the Treatment Paradigm of Oligorecurrent Prostate Cancer?
Although recent studies support the role of image-guided metastasis-directed therapies in the oligo-recurrent setting, several issues including the risk of possible underestimation of the true tumor burden at imaging, patient selection and the lack of studies comparing different approaches limit their implementation in the clinical practice. As such, metastasis-directed therapies should still be considered as investigational treatment options in oligo-recurrent prostate cancer patients.